It has been nearly fifteen years since the Food and Drug Administration (FDA) approved the first therapeutic cancer vaccine for solid tumors, namely Sipuleucel-T (Provenge), marking a significant milestone in the treatment of metastatic castration-resistant prostate cancer [...].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11546973 | PMC |
| http://dx.doi.org/10.3390/ijms252111521 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Curative immunotherapy-based strategies for non-metastatic non-small cell lung cancer.
Explor Target Antitumor Ther
December 2024
Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL 32224, US.
The emergence of immunotherapy has ushered in a new era in the management of non-small cell lung cancer (NSCLC). Various immune check point inhibitors have demonstrated significant benefit in the management of locally advanced NSCLC that are treated with either surgery or concurrent chemoradiation. We provide a comprehensive and up-to-date review of data from key studies, discuss the challenging clinical issue regarding the timing and duration of immunotherapy in patients undergoing surgery, and highlight the unmet needs and future directions of immunotherapy in NSCLC.
View Article and Find Full Text PDFArtificial intelligence in lung cancer: current applications, future perspectives, and challenges.
Front Oncol
December 2024
Department of Respiratory and Critical Care Medicine, Center for Respiratory Medicine, the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Artificial intelligence (AI) has significantly impacted various fields, including oncology. This comprehensive review examines the current applications and future prospects of AI in lung cancer research and treatment. We critically analyze the latest AI technologies and their applications across multiple domains, including genomics, transcriptomics, proteomics, metabolomics, immunomics, microbiomics, radiomics, and pathomics in lung cancer research.
View Article and Find Full Text PDFRadiomics and Artificial Intelligence in Pulmonary Fibrosis.
J Imaging Inform Med
January 2025
Laboratory of Computing, Medical Informatics and Biomedical Imaging Technologies, School of Medicine, Aristotle University of Thessaloniki, 54124, Thessaloniki, Greece.
A scoping review was conducted to investigate the role of radiological imaging, particularly high-resolution computed tomography (HRCT), and artificial intelligence (AI) in diagnosing and prognosticating idiopathic pulmonary fibrosis (IPF). Relevant studies from the PubMed database were selected based on predefined inclusion and exclusion criteria. Two reviewers assessed study quality and analyzed data, estimating heterogeneity and publication bias.
View Article and Find Full Text PDFConcomitant medication effects on patients with lung cancer taking immune checkpoint inhibitors a review.
Med Oncol
January 2025
Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin Road, Chengdu, Sichuan, China.
In the past decade, a variety of immune checkpoint inhibitors (ICIs) are currently approved for lung cancer in the world. As a new therapeutic approach, ICIs have shown significant clinical benefits in the first-line or second-line treatment for advanced lung cancer, improving the survival and quality of life of patients. Patients need to take multiple drugs in the meantime due to their own disease or side effects during treatment.
View Article and Find Full Text PDFCurrent advances and future prospects of blood-based techniques for identifying benign and malignant pulmonary nodules.
Crit Rev Oncol Hematol
January 2025
Department of Respiratory and Critical Care Medicine, Institute of Respiratory Health, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Institute of Respiratory Health, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China; Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address:
Lung cancer is the leading cause of cancer-related mortality worldwide, highlighting the urgent need for more accurate and minimally invasive diagnostic tools to improve early detection and patient outcomes. While low-dose computed tomography (LDCT) is effective for screening in high-risk individuals, its high false-positive rate necessitates more precise diagnostic strategies. Liquid biopsy, particularly ctDNA methylation analysis, represents a promising alternative for non-invasive classification of indeterminate pulmonary nodules (IPNs).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!